Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025

Key Takeaway: SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2025 on August 4, 2025, after market close. Management will host a conference call on the same day to discuss the results. The company is recognized for its innovative technologies in surgical treatments for sacropelvic disorders, having supported a significant number of procedures and backed by extensive clinical evidence.
Price reaction · baseline $17.2 (2025-07-11 close) · clean, no other SIBN news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is reporting promising financial results.
  • The company has a strong track record with over 125,000 procedures supported.
  • Their technologies are backed by over 175 peer-reviewed publications.

Full Press Release Details

SANTA CLARA, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the second quarter of 2025 after market close on Monday, August 4, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/fnam2tia/. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009 with the iFuse Implant System®, SI-BONE has supported over 4,500 physicians in performing a total of over 125,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies with over 175 peer reviewed publications including two randomized controlled trials. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation and pelvic trauma.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its Q2 2025 financial results?

SI-BONE will report Q2 2025 financial results after market close on August 4, 2025.

How can I listen to the SI-BONE conference call?

Register to listen to the call at https://edge.media-server.com/mmc/p/fnam2tia/.

Where can I find the SI-BONE webcast after the live call?

The webcast will be archived and available for replay on SI-BONE's website for 90 days.

What is SI-BONE known for in the medical device field?

SI-BONE specializes in unique technologies for the surgical treatment of sacropelvic disorders.

How many procedures has SI-BONE supported?

SI-BONE has supported over 125,000 procedures since its inception in 2009.

Last updated: Jul 14, 2025